A Neu View of Invasive Lobular Breast Cancer

Genome sequencing of relapsed, invasive lobular breast cancer identified actionable mutations in 86% of the cases. HER2 alterations occur in 27% of the cases, including 4 cases with activating HER2 mutations and 1 with a novel HER2–GRB7 gene fusion. This fusion links the HER2 tyrosine kinase domain to the GRB7 src homology 2 (SH2) domain. Clin Cancer Res; 19(13); 3331–3. ©2013 AACR.

[1]  James X. Sun,et al.  Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations , 2013, Clinical Cancer Research.

[2]  Li Ding,et al.  Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.

[3]  Wendy Winckler,et al.  Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2 , 2012, Proceedings of the National Academy of Sciences.

[4]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[5]  Nikolas von Bubnoff,et al.  Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib , 2011, PloS one.

[6]  B. Kreike,et al.  The molecular underpinning of lobular histological growth pattern: a genome‐wide transcriptomic analysis of invasive lobular carcinomas and grade‐ and molecular subtype‐matched invasive ductal carcinomas of no special type , 2010, The Journal of pathology.

[7]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[8]  R. Gelber,et al.  Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[10]  Carlos L Arteaga,et al.  HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. , 2006, Cancer cell.

[11]  R. Elledge,et al.  Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome , 2004, Breast Cancer Research.

[12]  James X. Sun,et al.  Relapsed classic E-cadherin (CDH1) mutated invasive lobular breast cancer demonstrates a high frequency of HER2 (ERBB2) gene mutations , 2013 .

[13]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.